| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.28 | 0.002 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.002 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.12 | 0.003 |